Active substances
Doxylamine + Pyridoxine
- SFDA 2
- US FDA 8
- Health Canada 4
- US price lines 3
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Xonvea | 10,10 mg,mg | Gastro-resistant tablet · Oral use | 30 Blister | SAR 109.10 | NCE · Prescription | Exeltis Healthcare S.L | Valid |
| Xonvea | 20,20 mg,mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 218.20 | NCE · Prescription | Exeltis Healthcare S.L | Valid |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DICLEGIS | 10MG;10MG | tablet, delayed release · oral | DUCHESNAY | Prescription | 8 Apr 2013 |
| DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE | 10MG;10MG | tablet, delayed release · oral | ACTAVIS LABS FL INC | Prescription | 19 Aug 2016 |
| BONJESTA | 20MG;20MG | tablet, extended release · oral | DUCHESNAY | Prescription | 7 Nov 2016 |
| DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE | 10MG;10MG | tablet, delayed release · oral | PH HEALTH | Prescription | 6 Dec 2017 |
| DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE | 10MG;10MG | tablet, delayed release · oral | BIONPHARMA | Prescription | 4 Aug 2023 |
| BENDECTIN | 10MG;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, extended release · oral | SANOFI AVENTIS US | Discontinued | 30 Jul 1956 |
| DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE | 10MG;10MG | tablet, delayed release · oral | PHARMOBEDIENT | Discontinued | 6 Jul 2020 |
| DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE | 20MG;20MG | tablet, extended release · oral | ACTAVIS LABS FL INC | Discontinued | 1 Mar 2022 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ALOG-DOXYLAMINE/PYRIDOXINE | 02552574 | 10 MG; 10 MG | TABLET (DELAYED-RELEASE) · ORAL | ANALOG PHARMA CANADA INC. |
| APO-DOXYLAMINE/B6 | 02413248 | 10 MG; 10 MG | TABLET (DELAYED-RELEASE) · ORAL | APOTEX INC |
| DICLECTIN | 00609129 | 10 MG; 10 MG | TABLET (DELAYED-RELEASE) · ORAL | DUCHESNAY INC |
| PMS-DOXYLAMINE-PYRIDOXINE | 02406187 | 10 MG; 10 MG | TABLET (DELAYED-RELEASE) · ORAL | PHARMASCIENCE INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | BONJESTA ER 20-20 MG TABLET | $11.11533 | per EA | 23 Sep 2026 |
| US NADAC | DICLEGIS DR 10-10 MG TABLET | $1.67584 | per EA | 23 Sep 2026 |
| US NADAC | DOXYLAMINE-PYRIDOXINE 10-10 MG | $1.09163 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Doxylamine 10mg / Pyridoxine 10mg gastro-resistant tablets | £28.50 | 20 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.